VPB1293 - Thromboinflammatory Biomarkers of Cardiorenal Syndrome in Patients Undergoing Maintenance Hemodialysis in End Stage Renal Disease

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Presenting Author(s)

Pranathi Karumanchi

Medical student
Loyola University Medical Center
Palatine, Illinois, United States

Co-Author(s)

VB

Vinod Bansal

Doctor
Loyola University Medical Center
Maywood, Illinois, United States
FS

Fakiha Siddiqui

Research Associate
Loyola University Medical Center
Maywood, Illinois, United States
DH

Debra Hoppensteadt

Professor
Loyola University Chicago
Chicago, Illinois, United States
JF

Jawed Fareed, n/a

Professor
Loyola University Medical Center
MAYWOOD, Illinois, United States

Background: Cardiovascular disease is a highly common complication in patients with end stage renal disease (ESRD) on maintenance hemodialysis. Current literature reveals that inflammation and thrombosis are integral to CRS development and key cardiac and renal biomarkers are elevated in CRS patients.

Aims: This study aims to demonstrate that thrombo-inflammatory biomarkers and laboratory parameters give a telling narrative of ESRD progression to CRS.

Methods: Plasma samples were collected from 95 ESRD patients which were recruited with an approved IRB. Normal human plasma (NHP) was obtained from a commercial. Thrombo-inflammatory biomarkers, including Annexin V, MPO, Troponin, L-FABP, VEGF, D-dimer, TNF-alpha, IL-6, CRP, eNOS, Nitrotyrosine, MDA, NEFA, NO, vWF and MCP-1 were measured using commercially available ELISA methods. Results were then statistically analyzed using GraphPad Prism v.9 ; the results were compiled into mean ± SEM, percent change comparison to NHP, analyzed for significance.

Results: Most of the thrombo-inflammatory CRS biomarkers were elevated in ESRD patients. Biomarkers including Annexin V (ESRD 7.57 ± 5.24, 23.64% vs. 6.125 ± 8.29, p< 0.001), L-FABP (106599.43 ± 176728.97, 1983% vs. 5116.33 ± 1767.88, p< 0.0001), D-dimer (ESRD 1447.01 ± 2103, 650.53% vs. 192.8 ± 212.9, p< 0.0001), TNF-alpha (ESRD 2.52 ± 1.06, 35.87% vs. 1.85 ± 1.20, p< 0.0001), IL-6 (ESRD 5.211 ± 10.36, 317.21% vs. 1.25 ± 1.24, p < 0.0001), CRP (ESRD 14.53 ± 14.11, 2214.43% vs. 0.63 ± 0.99, p< 0.0001), NO (ESRD 34.74 ± 19.74, 151.74% vs. 13.8 ± 5.60, p< 0.0001), vWF (ESRD 200.7 ± 25.89, 183.03% vs. 70.91 ± 23.13 p< 0.0001) and MCP-1 (148.4 ± 56.09, 67.49% vs. 88.6 ± 27.25, p< 0.0001) showed significant increase when compared to NHP.

Conclusion(s): This study suggests that thrombo-inflammatory biomarkers may be helpful in the understanding of the molecular pathogenesis of CRS in ESRD patients.